GoodRx Holdings, Inc. (GDRX)
$
3.83
+0.09 (2.35%)
Key metrics
Financial statements
Free cash flow per share
0.2659
Market cap
1.3 Billion
Price to sales ratio
1.6752
Debt to equity
0.0846
Current ratio
5.2253
Income quality
5.2975
Average inventory
0
ROE
0.0699
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
GoodRx Holdings, Inc., through its subsidiaries, offers valuable information and tools that empower consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform enabling consumers to access curated, geographically relevant prescription pricing and obtain negotiated prices through GoodRx codes. These codes facilitate significant savings on prescriptions nationwide. The company also provides additional healthcare products and services, including subscriptions, pharmaceutical manufacturer solutions, and telehealth services. Operating within this dynamic landscape, the company incurred an interest expense of $52,922,000.00 reflecting its debt servicing obligations. The gross profit ratio is 0.94 showcasing the efficiency of the company's production and sales operations. Furthermore, the total costs and expenses for the company are $726,478,000.00 which illustrates its overall spending. The company reported an income before tax of $31,460,000.00 highlighting its pre-tax profitability. Additionally, it incurred an income tax expense of $15,070,000.00 indicating its tax obligations. Incorporated in 2015 and headquartered in Santa Monica, California, the organization has made notable strides in the healthcare industry. The stock is affordable at $3.74 making it suitable for budget-conscious investors. Moreover, the stock enjoys a high average trading volume of 1,560,640.00 indicating strong liquidity in the market. With a market capitalization of $1,367,957,898.00 the company is classified as a small-cap player, reflecting its size relative to other companies. It is a key player in the Medical - Healthcare Information Services industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth in its field. This blend of affordability, liquidity, and market relevance positions GoodRx Holdings, Inc. as a noteworthy option for investors tracking developments in the healthcare market.
What is GoodRx Holdings, Inc. (GDRX)'s stock forecast?
Analysts predict GoodRx Holdings, Inc. stock to fluctuate between $3.68 (low) and $9.26 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is GoodRx Holdings, Inc.'s market capitalization?
As of 2025-05-27, GoodRx Holdings, Inc.'s market cap is $1,367,957,898, based on 357,169,164 outstanding shares.
How does GoodRx Holdings, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, GoodRx Holdings, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy GoodRx Holdings, Inc. (GDRX) stock?
To buy GoodRx Holdings, Inc. (GDRX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for GDRX. Place an order (Market, Limit, etc.).
What is the best time to invest in GoodRx Holdings, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did GoodRx Holdings, Inc. perform in the last earnings report?
Revenue: $792,324,000 | EPS: $0.04 | Growth: -285.19%.
Where can I find GoodRx Holdings, Inc.'s investor relations reports?
Visit https://www.goodrx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for GoodRx Holdings, Inc.?
You can explore historical data from here
What is the all-time high and low for GoodRx Holdings, Inc. stock?
All-time high: $59.67 (2021-02-10) | All-time low: $3.68 (2025-05-07).
What are the key trends affecting GoodRx Holdings, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
benzinga.com
JP Morgan analyst Lisa C. Gill revised her 2025 outlook on GoodRx Holdings GDRX following the company's first-quarter earnings.
zacks.com
Investors looking for stocks in the Medical Services sector might want to consider either GoodRx Holdings, Inc. (GDRX) or Progyny (PGNY). But which of these two stocks is more attractive to value investors?
seekingalpha.com
GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Aubrey Reynolds – Director-Investor Relations Wendy Barnes – President and Chief Executive Officer Chris McGinnis – Chief Financial Officer Conference Call Participants Lisa Gill – JPMorgan John Ransom – RJF Charles Rhyee – TD Cowen Jailendra Singh – Truist Securities Craig Hettenbach – Morgan Stanley George Hill – Deutsche Bank Steven Valiquette – Mizuho Securities Allen Lutz – Bank of America Michael Cherny – Leerink Partners Daniel Grosslight – Citi Operator Ladies and gentlemen, thank you for standing by and welcome to the GoodRx First Quarter 2025 Earnings Call. As a reminder, today's conference is being recorded.
zacks.com
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
Although the revenue and EPS for GoodRx (GDRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.08 per share a year ago.
zacks.com
GDRX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
seekingalpha.com
GoodRx is a great small-cap value stock to buy amid the recent downturn. I'm upgrading the stock to a buy. GoodRx showcases strong adjusted EBITDA despite slower growth, making it an attractive target for private equity deals as public equities become less appealing. The company's new CEO is driving a wholesale change in business strategy, chasing relationships directly with pharmaceutical manufacturers.
seekingalpha.com
GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Aubrey Reynolds - Director, IR Wendy Barnes - CEO Chris McGinnis - CFO Conference Call Participants Lisa Gill - J.P. Morgan John Ransom - RJF Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Jenny Cao - Truist Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Securities Steven Valiquette - Mizuho Securities Jay Jin - Morgan Stanley George Hill - Deutsche Bank Allen Lutz - Bank of America Operator Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx Fourth Quarter and Full Year 2024 Earnings Call.
zacks.com
While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
See all news
